1.Oh HJ., Yang DM., Kim CH., Jeon JG., Jung NH., Kim CY, et al. Exploring mortality rates for major causes of death in Korea. Open Public Health J. 2019. 12:16–25.
Article
2.American Diabetes Association. 9. Cardiovascular disease and risk management. Diabetes Care. 2017. 40(Suppl 1):S75–87.
3.Hirano T. Pathophysiology of diabetic dyslipidemia. J Atheroscler Thromb. 2018. 25:771–82.
Article
4.Bekele S., Yohannes T., Mohammed AE. Dyslipidemia and associated factors among diabetic patients attending Du-rame General Hospital in Southern Nations, Nationalities, and People's Region. Diabetes Metab Syndr Obes. 2017. 10:265–71.
5.Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010. 376:1670–81.
6.Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-anal-ysis of individual participant data from 28 randomised controlled trials. Lancet. 2019. 393:407–15.
7.Reaven GM. Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: the price paid to maintain glucose homeostasis in insulin-resistant individuals. Endocrinol Metab Clin North Am. 2005. 34:49–62.
Article
8.Wu L., Parhofer KG. Diabetic dyslipidemia. Metabolism. 2014. 63:1469–79.
Article
9.Bonilha I., Hajduch E., Luchiari B., Nadruz W., Le Goff W., Sposito AC. The reciprocal relationship between LDL metabolism and type 2 diabetes mellitus. Metabolites. 2021. 11:807.
Article
10.Srivastava RAK. Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease. Mol Cell Biochem. 2018. 440:167–87.
Article
11.Monaldi B., Bologna G., Costa GG., D'Agostino C., Ferrante F., Filice M, et al. Adherence to statin treatment following a myocardial infarction: an Italian population-based sur-vey. Clinicoecon Outcomes Res. 2015. 7:273–80.
12.Heeschen C., Hamm CW., Laufs U., Snapinn S., Böhm M., White HD. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002. 105:1446–52.
Article
13.Zhang L., Wang W., Man F., Pan Q., Guo L. The effect of statin adherence on patients with type 2 diabetes after percutaneous coronary intervention for acute coronary syndrome. Cardiovasc Drugs Ther 2022. DOI:
doi: 10.1007/s10557-021-07260-5. [Epub ahead of print].
14.Sposito AC., Carvalho LS., Cintra RM., Araújo AL., Ono AH., Andrade JM, et al. Rebound inflammatory response during the acute phase of myocardial infarction after sim-vastatin withdrawal. Atherosclerosis. 2009. 207:191–4.
Article
15.Rodriguez F., Maron DJ., Knowles JW., Virani SS., Lin S., Heidenreich PA. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2019. 4:206–13.
Article
16.Stephenson MC., Leverton E., Khoo EY., Poucher SM., Johansson L., Lockton JA, et al. Variability in fasting lipid and glycogen contents in hepatic and skeletal muscle tis-sue in subjects with and without type 2 diabetes: a 1H and 13C MRS study. NMR Biomed. 2013. 26:1518–26.
17.Tsalamandris C., Panagiotopoulos S., Allen TJ., Waldrip L., Van Gaal B., Goodall I, et al. Long-term intraindividual variability of serum lipids in patients with type I and type II diabetes. J Diabetes Complications. 1998. 12:208–14.
Article
18.Bardini G., Dicembrini I., Rotella CM., Giannini S. Lipids seasonal variability in type 2 diabetes. Metabolism. 2012. 61:1674–7.
Article
19.Rhee EJ., Han K., Ko SH., Ko KS., Lee WY. Increased risk for diabetes development in subjects with large variation in total cholesterol levels in 2,827,950 Koreans: a nationwide population-based study. PLoS One. 2017. 12:e0176615.
Article
20.Lee SH., Kim HS., Park YM., Kwon HS., Yoon KH., Han K, et al. HDL-cholesterol, its variability, and the risk of diabetes: a nationwide population-based study. J Clin Endocrinol Metab. 2019. 104:5633–41.
Article
21.Kwon YH., Kim SK., Cho JH., Kwon H., Park SE., Oh HG, et al. The association between persistent hypertriglyceridemia and the risk of diabetes development: The Kang-buk Samsung Health Study. Endocrinol Metab (Seoul). 2018. 33:55–61.
Article
22.Kreger BE., Odell PM., D'Agostino RB., Wilson PF. Long-term intraindividual cholesterol variability: natural course and adverse impact on morbidity and mortality–the Framingham Study. Am Heart J. 1994. 127:1607–14.
Article
23.Hsu WH., Lai CW., Chen SC., Chiou HC., Hsiao PJ., Shin SJ, et al. Greater low-density lipoprotein cholesterol variability increases the risk of cardiovascular events in patients with type 2 diabetes mellitus. Endocr Pract. 2019. 25:918–25.
Article
24.Wan EYF., Yu EYT., Chin WY., Barrett JK., Mok AHY., Lau CST, et al. Greater variability in lipid measurements associated with cardiovascular disease and mortality: a 10-year diabetes cohort study. Diabetes Obes Metab. 2020. 22:1777–88.
Article
25.Wang MC., Li CI., Liu CS., Lin CH., Yang SY., Li TC, et al. Effect of blood lipid variability on mortality in patients with type 2 diabetes: a large single-center cohort study. Cardiovasc Diabetol. 2021. 20:228.
Article
26.Sheng CS., Miao Y., Ding L., Cheng Y., Wang D., Yang Y, et al. Prognostic significance of visit-to-visit variability, and maximum and minimum LDL cholesterol in diabetes mellitus. Lipids Health Dis. 2022. 21:19.
Article
27.Gosmanova EO., Mikkelsen MK., Molnar MZ., Lu JL., Yes-sayan LT., Kalantar-Zadeh K, et al. Association of systolic blood pressure variability with mortality, coronary heart disease, stroke, and renal disease. J Am Coll Cardiol. 2016. 68:1375–86.
28.Kim MK., Han K., Kim HS., Park YM., Kwon HS., Yoon KH, et al. Effects of variability in blood pressure, glucose, and cholesterol concentrations, and body mass index on endstage renal disease in the general population of Korea. J Clin Med. 2019. 8:755.
Article
29.Li L., Wang F., Xu M., Lu JL., Zhao ZY., Li M, et al. Association of visit-to-visit variabilities in metabolic factors with chronic kidney disease in Chinese adults living in Shang-hai. Biomed Environ Sci. 2021. 34:761–72.
30.Chang YH., Chang DM., Lin KC., Hsieh CH., Lee YJ. High-density lipoprotein cholesterol and the risk of ne-phropathy in type 2 diabetic patients. Nutr Metab Cardiovasc Dis. 2013. 23:751–7.
Article
31.Ceriello A., De Cosmo S., Rossi MC., Lucisano G., Geno-vese S., Pontremoli R, et al. Variability in HbA
1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes. Diabetes Obes Metab. 2017. 19:1570–8.
Article
32.Matsuoka-Uchiyama N., Uchida HA., Okamoto S., Onishi Y., Katayama K., Tsuchida-Nishiwaki M, et al. The association of postprandial triglyceride variability with renal dysfunction and microalbuminuria in patients with type 2 diabetic mellitus: a retrospective and observational study. J Diabetes Res. 2022. 2022:3157841.
Article
33.Wan EYF., Yu EYT., Chin WY., Lau CST., Mok AHY., Wang Y, et al. Greater variability in lipid measurements associated with kidney diseases in patients with type 2 diabetes mellitus in a 10-year diabetes cohort study. Sci Rep. 2021. 11:8047.
Article
34.Epstein M., Vaziri ND. Statins in the management of dyslipidemia associated with chronic kidney disease. Nat Rev Nephrol. 2012. 8:214–23.
Article
35.Mann DM., Glazer NL., Winter M., Paasche-Orlow MK., Muntner P., Shimbo D, et al. A pilot study identifying statin nonadherence with visit-to-visit variability of low-den-sity lipoprotein cholesterol. Am J Cardiol. 2013. 111:1437–42.
Article
36.Kim MK., Han K., Park YM., Kwon HS., Kang G., Yoon KH, et al. Associations of variability in blood pressure, glucose and cholesterol concentrations, and body mass index with mortality and cardiovascular outcomes in the general population. Circulation. 2018. 138:2627–37.
Article
37.Smit RAJ., Jukema JW., Postmus I., Ford I., Slagboom PE., Heijmans BT, et al. Visit-to-visit lipid variability: clinical significance, effects of lipid-lowering treatment, and (pharmaco) genetics. J Clin Lipidol. 2018. 12:266–76.e3.
Article
38.Bangalore S., Breazna A., DeMicco DA., Wun CC., Messerli FH. Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial. J Am Coll Cardiol. 2015. 65:1539–48.
39.Keating AJ., Campbell KB., Guyton JR. Intermittent non-daily dosing strategies in patients with previous statin-in-duced myopathy. Ann Pharmacother. 2013. 47:398–404.
Article
40.Qamar A., Giugliano RP., Keech AC., Kuder JF., Murphy SA., Kurtz CE, et al. Interindividual variation in low-density lipoprotein cholesterol level reduction with evolocumab: an analysis of FOURIER trial data. JAMA Cardiol. 2019. 4:59–63.
Article